$PFE (Pfizer Inc.)

$PFE {{ '2016-10-10T11:15:00+0000' | timeago}} • Announcement

$PFE announced data from an ongoing, investigational Phase 1b study of Inlyta in a treatment-naive patients with advanced renal cell carcinoma (RCC), a common type of kidney cancer. The data from a trial of Inlyta wth pembrolizumab provides additional support for novel immunotherapy combinations in RCC.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$PFE {{ '2017-08-17T19:23:27+0000' | timeago}} • Announcement

The US FDA has approved $PFE's rare blood cancer drug BESPONSA. The U.S. labeling for BESPONSA includes a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease (VOD) and increased risk of post-HSCT non-relapse mortality.

$PFE {{ '2017-08-01T18:57:28+0000' | timeago}} • Webcast

$PFE expects five different potential blockbuster approvals in Oncology division and three potential blockbusters in Vaccines over the next five years. In addition, the company has 14 distinct biosimilar assets in the pipeline, eight of which are in mid-to-late stage development and six assets are in the early stage.

$PFE {{ '2017-08-01T18:56:05+0000' | timeago}} • Webcast

Over the next five years, $PFE projects the potential for about 25 to 30 approvals, of which up to 15 have the potential to be blockbusters. The company expects to receive approval for half of those potential blockbusters by 2020.

$PFE {{ '2017-08-01T14:15:55+0000' | timeago}} • Announcement

Top sellers including Lyrica, Ibrance and Eliquis produced higher sales, helping lift sales from $PFE’s Innovative Health segment by 8% in 2Q17. The company's Essential Health segment had sales dip 14% mostly due to few products losing marketing exclusivity. Sales of rheumatoid arthritis treatment Enbrel tumbled 20% on competition from biosimilars.

$PFE {{ '2017-08-01T14:05:53+0000' | timeago}} • Announcement

$PFE raised the low end of its FY17 adjusted earnings guidance, citing reduced expenses and higher-than-expected royalty income from certain products. The drugmaker now expects earnings in a range of $2.54 to $2.60 per share, compared to its prior forecast of $2.50 to $2.60. It still expects to generate between $52-54Bil of sales this year.

$PFE {{ '2017-08-01T14:04:26+0000' | timeago}} • Announcement

With rising sales from key products, profit at $PFE grew 50% YoY in 2Q17, but sales dropped for the third quarter in a row. The company attributes the 2% decline in sales to the divestment of its infusions business and foreign exchange fluctuations. The Viagra maker posted earnings of $3.1Bil, or $0.51 per share, on revenue of $12.9Bil.

$PFE {{ '2017-08-01T11:56:57+0000' | timeago}} • Infographic

$PFE Pfizer Earnings AlphaGraphic: Q2 2017 Highlights

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$PFE {{ '2017-07-24T15:56:36+0000' | timeago}} • Announcement

$PFE's REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin, met its primary objective. PF-06439535 is being developed by $PFE as a potential biosimilar to Avastin. Results demonstrate equivalence in objective response rate in patients with advanced non-squamous non-small cell lung cancer.

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$PFE {{ '2017-07-13T12:13:49+0000' | timeago}} • Announcement

The FDA has accepted $PFE's filing of supplemental New Drug Application (sNDA) for XELJANZ (tofacitinib citrate), an investigational oral treatment for adult patients with moderately to severely active ulcerative colitis. The FDA has provided an anticipated Prescription Drug User Fee Act action date in March 2018 for the sNDA.

$PFE {{ '2017-07-12T11:41:14+0000' | timeago}} • Announcement

$PFE said the FDA's Oncologic Drug Advisory Committee (ODAC) voted that the results of ALFA-0701 demonstrated a favorable risk benefit profile for Mylotarg on days 1, 4 and 7 added to chemotherapy for patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).

$PFE {{ '2017-07-11T20:58:23+0000' | timeago}} • Announcement

The US FDA's Oncologic Drug Advisory Committee (ODAC) voted in favor of $PFE's MYLOTARG (gemtuzumab ozogamicin), an antibody-drug conjugate used to treat acute myeloid leukemia. The role of the ODAC is to provide recommendations to the FDA. The FDA decision on whether or not to approve MYLOTARG is anticipated by Sept. 2017.

$PFE {{ '2017-06-30T12:36:12+0000' | timeago}} • Announcement

$PFE received approval for its Besponsa as monotherapy from the European Commission. The Besponsa was approved for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). ALL is an aggressive type of leukemia that can be fatal within a matter of months if left untreated.

$PFE {{ '2017-06-27T13:34:31+0000' | timeago}} • Announcement

$PFE broke ground on its new R&D and process development facility in Chesterfield, Missouri. Construction is expected to be complete by mid-2019. The facility will house more than 450 employees who currently work at multiple locations, and an additional 80 employees that the company expects to hire over the coming years.

$PFE {{ '2017-06-22T20:52:12+0000' | timeago}} • Announcement

$PFE declared a $0.32 3Q17 dividend on the company’s common stock, payable September 1, 2017, to shareholders of record as on August 4, 2017.

$ACET {{ '2017-06-20T14:58:15+0000' | timeago}} • Announcement

$ACET said its finished dosage form generics subsidiary Rising Pharmaceuticals has launched Glipizide Extended Release Tablets, an FDA-approved generic version of the reference listed drug, Glucotrol XL from $PFE. Glipizide are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Recent Transcripts

FATE (Fate Therapeutics, Inc.)
Monday, August 14 2017 - 9:00pm
ARRY (Array BioPharma Inc.)
Wednesday, August 9 2017 - 1:00pm
VCEL (Vericel Corporation)
Wednesday, August 9 2017 - 12:00pm
ECYT (Endocyte, Inc.)
Tuesday, August 8 2017 - 8:30pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
ESPR (Esperion Therapeutics, Inc.)
Tuesday, August 8 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
HAE (Haemonetics Corporation)
Monday, August 7 2017 - 12:00pm
EPZM (Epizyme, Inc.)
Friday, August 4 2017 - 12:00pm
EBS (Emergent BioSolutions, Inc.)
Thursday, August 3 2017 - 9:00pm
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
FVE (Five Star Quality Care Inc.)
Wednesday, August 2 2017 - 2:00pm
HUM (Humana Inc.)
Wednesday, August 2 2017 - 1:00pm
PCRX (Pacira Pharmaceuticals, Inc.)
Wednesday, August 2 2017 - 12:30pm
HLF (Herbalife Ltd.)
Tuesday, August 1 2017 - 9:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
FMS (Fresenius Medical Care AG & Co. KGAA)
Tuesday, August 1 2017 - 1:30pm
HLS (HEALTHSOUTH Corp.)
Tuesday, August 1 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, July 28 2017 - 12:30pm

AlphaGraphics you may like